Drugs in MeSH Category Sleep Aids, Pharmaceutical

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
New River	DOXEPIN HYDROCHLORIDE	doxepin hydrochloride	CAPSULE;ORAL	016987-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Msn	DOXEPIN HYDROCHLORIDE	doxepin hydrochloride	CAPSULE;ORAL	215113-003	Jun 24, 2022	AB	RX	No	No
Elkins Sinn	DIPHENHYDRAMINE HYDROCHLORIDE	diphenhydramine hydrochloride	CAPSULE;ORAL	085701-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Fosun Pharma	DIPHENHYDRAMINE HYDROCHLORIDE	diphenhydramine hydrochloride	CAPSULE;ORAL	080845-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Roxane	DIPHENHYDRAMINE HYDROCHLORIDE	diphenhydramine hydrochloride	ELIXIR;ORAL	080643-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Currax	SILENOR	doxepin hydrochloride	TABLET;ORAL	022036-002	Mar 17, 2010	AB	RX	Yes	Yes	9,907,780		Y

Last updated: June 8, 2026

Market dynamics and patent landscape for Sleep Aids (NLM MeSH: Sleep Aids, Pharmaceutical)

Sleep-aids patent estates are concentrated in a small set of branded small molecules (notably zolpidem, eszopiclone, ramelteon, lemborexant, suvorexant, daridorexant, zaleplon) and a separate track for opioid use disorder sleep-related indications. Commercial value is driven by insomnia prevalence, payer restriction patterns (step edits, prior auth, quantity limits), and the sequencing of “first-in-class” orexin antagonists versus older GABAergic hypnotics. Patent risk for generics is mostly managed by late-claim formulation and polymorph/process families, while regulatory entry timing is shaped by Orange Book exclusivities, including use-code and new-chemical-entity (NCE) where applicable.

Quick market and IP map (where exclusivity and patents concentrate)

Drug (active)	MeSH-relevant category	Commercial role in insomnia	Typical patent hooks for blocking generics	Main competitive pressure
Zolpidem (incl. ER)	GABA-A hypnotic	Large-volume chronic insomnia franchise (historically)	Formulation (ER beads/matrix), polymorphs, process, method-of-use	Loss of remaining patents drives generic consolidation
Eszopiclone	GABA-A hypnotic	Share vs. zolpidem via tolerability and dosing convenience	Polymorph/formulation and salt form refinements	Generic price compression post-expiry
Zaleplon	GABA-A hypnotic	Smaller volume, niche insomnia positioning	Formulation/process	Limited brand vs generic
Ramelteon	MT1/MT2 agonist	Premium vs sedatives, but smaller absolute share	Drug substance/formulation + method-of-use	Generic entry risk post-expiry
Orexin antagonists: lemborexant, suvorexant, daridorexant	Sleep maintenance/insomnia	Growth engines tied to “next-class” mechanism	Crystal forms, exposure-controlled formulations, use and dosing patents	Clinicians’ shift to orexin class drives demand
New delivery tech (titration/controlled release)	Delivery system	Extends life via differentiation	ER/IR delivery-method patents	“Copycat” formulation challenges

Source basis: NLM MeSH scope is “Sleep Aids, Pharmaceutical,” which covers approved pharmaceutical hypnotics and sleep-modulating agents used to treat insomnia and related sleep disorders. (MeSH entry cited in References.)

---

How do patent estates shape competition for sleep aid drugs?

Answer: Patent estates in insomnia are won through layered coverage: (1) composition of matter (drug substance or specific crystal form), (2) formulations (controlled release, IR/ER architecture, dose strength-specific claims), (3) manufacturing/process claims, and (4) method-of-use claims where dosing schedules and therapeutic window are claimed. The result is that generic risk often depends less on the first composition patent and more on late-expiring formulation or use-code families listed in the Orange Book.

What kinds of patents dominate sleep-aid Orange Book listings?

1. Controlled-release architecture
   • ER hypnotics frequently have claims tied to polymer matrices, bead systems, coating systems, or dissolution/erosion profiles that map to clinical exposure curves.
2. Polymorphs and crystalline forms
   • Many insomnia APIs are sold in specific crystalline forms; later patents often narrow to a form with improved stability, manufacturability, or bioavailability.
3. Process and yield improvements
   • Multiple continuation applications can extend enforceability by tying to improved reaction conditions, purification steps, and crystallization parameters.
4. Method-of-use and dosing
   • Orexin antagonists and some melatonin-pathway agents include dosing-interval claims, sleep-maintenance endpoints, or prescriber-use patterns.

Which legal mechanisms matter most for sleep aids?

• Paragraph IV certifications against Orange Book patents are the primary generic launch lever for mature hypnotics. Settlement patterns are common where late-expiring formulation or process patents are asserted.
• Use-code and pediatric exclusivities can delay generic approval even after composition expiry.

---

When do sleep-aid patents expire and how long do FDA exclusivities delay generics?

Answer: Generic entry timing is a function of both patent expiry and FDA exclusivity attached to the listed NDA/BLA. For sleep aids, exclusivity is often shorter than patent life when the brand is a mature product; when remaining patents sit in formulation/use families, exclusivity can matter less than Orange Book listing status.

Patent-expiry vs. exclusivity: how market entry typically unfolds

Phase	What drives launch	Sleep-aid implication
1. Brand still protected by composition patents	Orange Book patents block ANDA approval	Generic entry usually delayed
2. Composition expiry but formulation/process patents remain	ANDA can be submitted, launch depends on litigation or “carve-out”	Entry often delayed by settlements or FDA stay
3. Exclusivity remains (NCE/pediatric/other)	FDA cannot approve even if patents expire	Can extend the effective brand window
4. Final patent expiry	ANDA approval and launch become feasible	Price compression begins

Source basis: Orange Book timing concepts are used to frame insomnia launch dynamics; MeSH establishes class scope. (FDA/Orange Book sources cited.)

---

What patents protect zolpidem, eszopiclone, and zaleplon from generic entry?

Answer: For GABA-A hypnotics, generic blocking is most often anchored in controlled-release formulation patents and stable polymorph/process claims. Market dynamics after first composition expiry tend to show gradual share shift as “best-fit” generic formulations (bioequivalent with the right release profile) become available.

Zolpidem (including ER): where the patent estate usually concentrates

• Controlled-release composition and structure: polymer matrix/bead systems that control Tmax and Cmax.
• Specific dosage forms: patents can be strength-specific (e.g., 6.25 mg ER vs 12.5 mg ER).
• Method-of-use: sometimes covers sleep-onset vs sleep-maintenance endpoints depending on label language.

Eszopiclone and zaleplon: typical protection pattern

• Polymorph/form and manufacturing claims that improve shelf life and batch consistency.
• Formulation improvements targeted at exposure, dissolution, or stability.

Competitive market effect: Once the strongest formulation patents fall, generic consolidation accelerates and price declines are steeper in payer-incentivized markets (formularies that prefer lower WAC).

---

What patents protect orexin antagonists like lemborexant, suvorexant, and daridorexant?

Answer: Orexin antagonists carry strong patent estates tied to crystalline forms and delivery/exposure control, plus method-of-use families aligned to insomnia subpopulations (sleep onset vs maintenance, dose titration). The orexin class has also benefited from clinical differentiation, increasing willingness to pay for branded therapy while IP is active.

Lemborexant, suvorexant, daridorexant: typical IP levers

• Drug substance crystal form and salt/polymorph
• Formulation and exposure profile
• Method-of-treatment claims (insomnia endpoints consistent with label differentiation)
• Combination or titration regimens where claimed

Biosimilar risk?

Not applicable in a strict biosimilar sense because these sleep aids are small molecules, not biologics. Competitive “biosimilar-like” dynamics in this space come from interchangeability of generics rather than biologic pathway regulation.

---

Which companies are positioned to launch generics of sleep aids, and what barriers do they face?

Answer: Generic launch capability exists broadly across major ANDA filers, but barriers cluster around (1) Orange Book patent lists tied to formulations and processes and (2) litigation-driven settlement and FDA approval timing. The effective barrier is not only IP validity but also whether a generic can clear the exact Orange Book patent claim scope.

Practical barriers for generic ANDAs in sleep aids

• Bioequivalence plus release-profile risk for ER formulations
• Design-around limits: if patents cover broad formulation categories, workarounds can still land within claim scope
• Litigation and stays: a Paragraph IV contest can trigger FDA approval delays via statutory stays

---

What is the Orange Book status of sleep-aid drugs?

Answer: Orange Book status for sleep-aid brands is defined by whether patents are listed as covering the approved drug product (use-code or drug substance/formulation patents) and whether FDA exclusivities remain. The practical implication is that even when a composition patent expires, generics may be blocked by remaining formulation/process/use-code listings.

How to read Orange Book leverage in sleep aids

• If a generic targets an Orange Book use-code patent, launch timing hinges on that patent’s status (expiry or litigation outcome).
• Formulation patents frequently have later expiries, which sustains brand exclusivity longer than composition patents alone.

(Orange Book methodology is cited in References.)

---

What patent litigation affects sleep aids and how do settlements shape market entry?

Answer: Sleep-aid litigation is typically concentrated on formulation and method-of-use patents with later expirations. Settlements often translate into delayed launches, sometimes with “authorized generic” arrangements or stipulated launch dates.

Common litigation outcomes in insomnia patent portfolios

• Partial win for brands leads to approval delays for certain generic strengths or dosage forms.
• Settlements convert contested patent risk into a fixed launch window.
• Design-around approvals can occur when the generic product avoids specific formulation/process claim scope.

---

How do formulation patents create late-life brand extensions in sleep aids?

Answer: Formulation patents extend life by covering specific release mechanisms, dosage strengths, particle/crystal characteristics, and manufacturing parameters that determine bioavailability. This creates a scenario where composition expiry does not translate into immediate generic interchange.

Formulation/IP interaction patterns

Formulation feature	Example claim theme	Generic risk
Controlled release	Polymer matrix/beads/coating	High if claim breadth is broad
Particle size/crystal stability	Polymorph-specific control	Moderate to high
Dissolution profile	Release-rate targets	Moderate
Strength-specific dosing	Coverage for specific mg	High for multi-strength products

---

How strong is the patent estate for sleep aids by mechanism class?

Answer: The highest residual strength is usually in orexin antagonists due to later-generation patents and sustained demand, while mature GABA-A hypnotics rely more heavily on remaining formulation/process families once composition patents lapse.

Strength ranking framework (practical, litigation-ready)

1. Late-expiring formulation/process families
2. Multiple overlapping use-code patents
3. Credible infringement theories tied to dosage form and release profile
4. Litigation history indicating enforceability
5. Potential for design-around with narrow claim sets

---

What generic entry risks exist for sleep aids after patent and exclusivity dates?

Answer: Entry risk is highest when multiple Orange Book patents remain in force, especially formulation/process families. Risk decreases when only a single expiring patent remains and when there is clear design-around room.

Generic entry scenario table

Scenario	Conditions	Market impact
Clean entry	No Orange Book patents left or litigation cleared	Fast price erosion
Delayed entry via settlement	Brand settles on a future launch date	Predictable brand revenue protection
Strength-limited entry	Generic launches only certain strengths/dosage forms	Brand retains share in protected strengths
Launch but with risk	Patent still in force and injunction possible	Leverages litigation as a threat

---

Which MeSH “Sleep Aids, Pharmaceutical” drugs carry the biggest revenue exposure from patent expiry?

Answer: Revenue exposure is concentrated in the largest-volume insomnia franchises and growth orexin antagonists. In practice, the biggest exposure comes from the intersection of (1) high prescription volume, (2) multiple strengths, and (3) patents with staggered expiries.

Revenue exposure drivers (business relevance)

• ER product lines with multi-strength SKUs have more patent surface area.
• Dose-form differentiation can prolong brand advantage when generics are slower to match release profile.
• Payer restrictions magnify substitution impact: when generics gain formulary preference, uptake accelerates.

---

How does the sleep-aid patent landscape differ by jurisdiction?

Answer: US Orange Book controls ANDA timing for US launch. Outside the US, the controlling variable is whether national filings cover formulation/process and whether courts enforce patents that align with generics’ manufacturing routes. Many insomnia brands build global filing strategies around formulation and crystalline form, which tends to be easier to map to generic product attributes.

(US-focused regulatory entry timing is central to this analysis.)

---

Key Takeaways

• Sleep-aid competition is shaped by layered IP: composition plus late-expiring formulation/process and use-code patents.
• Orange Book status is the practical gate for generic approval timing; composition expiry alone usually does not end brand protection.
• Controlled-release formulations and polymorph/crystal form families are the most common barriers to generic entry in insomnia.
• Orexin antagonists typically carry stronger residual patent protection, aligning with continued branded demand.
• Litigation and settlements tend to translate contested IP into predictable launch dates, often protecting specific strengths or dosage forms.

---

FAQs

1. What patent claim types most often trigger Paragraph IV challenges for insomnia drugs?
2. How do formulation patents affect ANDA approval for extended-release sleep aids?
3. What Orange Book use-code patents delay generic approval of sleep aids even after composition expiry?
4. Do orexin antagonists face the same generics timing dynamics as GABA-A hypnotics?
5. How do settlement terms in insomnia patent cases typically limit generic entry?

---

References

1. National Library of Medicine (NLM). MeSH: Sleep Aids, Pharmaceutical.
2. U.S. Food and Drug Administration (FDA). Drugs@FDA.
3. U.S. Food and Drug Administration (FDA). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.